Licensing Terms and Agreements in Pharma, Biotech and Diagnostics

1
Licensing Terms and Agreements in Pharma,
Biotech and Diagnostics
One-Stop Shop for Business Information
2
Summary
The Licensing Terms and Agreements in Pharma,
Biotech and Diagnostics report provides
comprehensive understanding and unprecedented
access to the licensing deals and agreements
entered into by the worlds leading life science
companies. The report provides a detailed
understand and analysis of how and why companies
enter licensing deals. Understanding the
flexibility of a prospective partners negotiated
deals terms provides critical insight into the
negotiation process in terms of what you can
expect to achieve during the negotiation of terms.
3
This report contains links to online copies of
actual licensing contract documents as submitted
to the Securities Exchange Commission by
biopharma companies and their partners. Contract
documents provide the answers to numerous
questions about a prospective partners
flexibility on a wide range of important issues,
many of which will have a significant impact on
each partys ability to derive value from the
deal. The initial chapters of this report
provide an orientation of licensing dealmaking
and business activities.
4
Chapter 1 provides an introduction to the
report, whilst Chapter 2 provides an analysis of
the trends in licensing as well as a discussion
on the merits of the type of deal. Chapter 3
provides an overview of the structure of
licensing deals. The chapter includes numerous
case studies to enable understanding of both pure
licensing deals and multicomponent deals where
licensing forms a part. Chapter 4 provides a
review of the leading licensing deals since 2009.
Deals are listed by headline value, signed by
bigpharma, most active bigpharma, signed by
bigbiotech, most active bigbiotech, and most
active of all biopharma companies. Where the deal
has an agreement contract published at the SEC a
link provides online access to the contract via
the Current Agreements deals and alliances
database.
5
Chapter 5 provides a comprehensive review of
licensing financials for deals announced since
2009, including headline value, upfront,
milestone payments and royalty rates by stage of
development, providing both benchmark data and
access to individual deal financials.Chapters 6
and 7 provide a comprehensive listing of the top
50 bigpharma and bigbiotech companies with a
brief summary followed by a comprehensive listing
of licensing deals available in the public
domain. Where available, each deal title links
via Current Agreements deals and alliances
database to an online version of the actual
contract document, providing easy access to each
contract document on demand.
6
Chapter 8 provides a comprehensive and detailed
review of licensing deals signed and announced
since 2009 where a contract document is
available. The chapter is organized by company
A-Z, stage of development at signing,
technologyand therapeutic area. Each deal title
links via Weblink to an online version of the
actual contract document, providing easy access
to each contract document on demand .The report
also includes numerous table and figures that
illustrate the trends and activities in licensing
dealmaking since 2009. In conclusion, this
report provides everything a prospective
dealmaker needs to know about licensing
dealmaking, enabling thorough learning, education
and due diligence prior and during the licensing
dealmaking process.
7
Table Of Content

• Chapter 1 Introduction
• Chapter 2 Trends in licensing dealmaking
• Chapter 3 Overview of licensing deal structure
• Chapter 4 Leading licensing deals
• Chapter 5 Licensing deal term benchmarks
• Chapter 6 Bigpharma licensing deals
• Chapter 7 Bigbiotech licensing deals
• Chapter 8 Licensing contract directory 2009-2014

8

• To know more Licensing Terms and Agreements
  in Pharma, Biotech and Diagnostics

Contact Us-Call India 91-22-27810772/73 Call
USA/Canada (Toll Free) 1-866-279-8368 Email id
info_at_bharatbook.com